The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.

Disclosed are vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/rl or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.

The present application relates a composite multi-epitope expression cassette, a recombinant virus composed thereof and application thereof, and in particular to a chimeric recombinant Newcastle disease virus inserted with an IBV epitope cassette and a vaccine prepared by using the virus. The expression cassette comprises: (a) T cell epitopes derived from S1 proteins of avian infectious bronchitis virus Holte strain and avian infectious bronchitis virus QX-like strain; and (b) B cell epitopes derived from S1 protein of avian infectious bronchitis virus Australian T strain. In the present application, the multi-epitope chimeric ST/B gene of avian infectious bronchitis virus is inserted into the backbone of LaSota strain, so that the LaSota strain can express S1-T/B protein. Thus, the purpose of preventing both ND and IB diseases is achieved. In addition, the T cell epitopes and B cell epitopes act synergistically to produce an earlier and more comprehensive immune response against virus.

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.

The present disclosure relates to a vaccine composition for preventing human infection SARS-CoV-2 (COVID-19) and alleviating infection symptoms, and the vaccine composition including a recombinant Newcastle disease virus on the surface of which the SARS-CoV-2 RBD protein of the present disclosure is expressed or antigen purified therefrom induces an immune response that can fight COVID-19 infection so that it can be useful as a vaccine for preventing and treating SARS-CoV-2 infection.

The present invention provides a gene recombinant respiratory syncytial virus (RSV) in which genes encoding the envelope proteins of an RSV are rearranged, wherein in the RSV, a gene encoding the fusion protein (F protein) derived from a heterologous virus belonging to the family Paramyxoviridae or the family Pneumoviridae is inserted between the genes respectively encoding the glycoprotein (G protein) and the F protein of the RSV, or the gene encoding the F protein of the RSV is substituted with a gene encoding the F protein of a heterologous virus belonging to the family Paramyxoviridae or the family Pneumoviridae. The recombinant RSV of the present invention can be used as an RSV vaccine strain, and can be used as a vaccine due to having excellent stability and safety.

This application discloses methods, compositions, and articles of manufacture for using NDV-induced serum to treat non-human mammals, including dogs, displaying severe neurological symptoms of advanced canine distemper virus (CDV) infection. An off-the-shelf chicken vaccine is injected into two or more healthy mammals, of the same species as the sick animal, to provoke an immune response. After allowing several hours for the immune response to develop, blood is drawn from the healthy mammals and centrifuged to obtain serum. This “NDV-induced serum” can be injected into a mammal of the same species displaying severe neurological symptoms of advanced CDV infection on a prescribed schedule to bolster the sick animal's immune responses, preferably leading to clearance of the virus without the need for a spinal tap, which is the standard treatment for advanced CDV infection in mammals.

Field of application: the invention relates to veterinary medicine and, in particular, to vaccinology and pharmacy, and is intended for the prevention and treatment of infectious and other diseases of humans and animals, where low allergenic low reactogenic vaccination is used. The essence of the invention: developed vaccines with increased immunogenicity, low allergenicity and reactogenicity, containing antigen/toxin and adjuvant, wherein that they contain vaccine antigen/toxin inactivated by electromagnetic radiation in the ultraviolet and visible regions of the spectrum in the presence of a solution of photosensitizer and salts of divalent metals, and then covalently modified according to the residues of amino groups and hydroxyls groups of antigen/toxin available for modification, at least two modifying agents at the same time in terms of 0.01-10.0% of the mass concentration of the antigen/toxin protein, and as an adjuvant it contains hydrosol hydroxide ferric chloride.

The present application relates a composite multi-epitope expression cassette, a recombinant virus composed thereof and application thereof, and in particular to a chimeric recombinant Newcastle disease virus inserted with an IBV epitope cassette and a vaccine prepared by using the virus. The expression cassette comprises: (a) T cell epitopes derived from S1 proteins of avian infectious bronchitis virus Holte strain and avian infectious bronchitis virus QX-like strain; and (b) B cell epitopes derived from S1 protein of avian infectious bronchitis virus Australian T strain. In the present application, the multi-epitope chimeric ST/B gene of avian infectious bronchitis virus is inserted into the backbone of LaSota strain, so that the LaSota strain can express S1-T/B protein. Thus, the purpose of preventing both ND and IB diseases is achieved. In addition, the T cell epitopes and B cell epitopes act synergistically to produce an earlier and more comprehensive immune response against virus.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.